Cargando…

The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study

BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019...

Descripción completa

Detalles Bibliográficos
Autores principales: Manvi, Sujaya, Mahajan, Vikram K., Mehta, Karaninder S., Chauhan, Pushpinder S., Vashist, Sanket, Singh, Ravinder, Kumar, Prabal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809144/
https://www.ncbi.nlm.nih.gov/pubmed/35198464
http://dx.doi.org/10.4103/idoj.idoj_530_21
_version_ 1784643958780985344
author Manvi, Sujaya
Mahajan, Vikram K.
Mehta, Karaninder S.
Chauhan, Pushpinder S.
Vashist, Sanket
Singh, Ravinder
Kumar, Prabal
author_facet Manvi, Sujaya
Mahajan, Vikram K.
Mehta, Karaninder S.
Chauhan, Pushpinder S.
Vashist, Sanket
Singh, Ravinder
Kumar, Prabal
author_sort Manvi, Sujaya
collection PubMed
description BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019 were analyzed retrospectively for clinical attributes, putative drugs and their indications, extracutaneous complications, and therapeutic outcome. The diagnosis was clinical based on established criteria. WHO-UMC scale for reporting ADR and ALDEN algorithm score were used for causality assessment. Therapies were customized based on in-house resources and affordability. RESULTS: Cases included were SJS (41.9%), SJS/TEN overlap (33.9%), and TEN (24.2%) aged 4–85 years. Complications included transaminitis (69.4%), lymphadenopathy (15.5%), septicemia (11.3%), and wound infections (4.8%). Aromatic anticonvulsants (37.1%), disease-modifying antirheumatic drugs (25.8%), antiretroviral drugs (12.9%), non-steroidal anti-inflammatory drugs (8.1%), antimicrobials (4.8%), and trihexyphenidyl (3.2%) were major putative drugs. The mean latent period was 16.6 days. The observed 8% mortality was because of primary comorbidities or multiorgan failure. Addition of fresh blood transfusion (BT, n = 11) or IVIg (n = 7) to systemic corticosteroids showed early relief in skin tenderness, improvement in general condition, and re-epithelialization. Only 16% of patients developed sequelae. CONCLUSION: Aromatic anticonvulsants, allopurinol, nevirapine, cotrimoxazole, paracetamol, and diclofenac remain the most implicated drugs. Sulfasalazine, leflunomide, ethambutol, and trihexyphenidyl were uncommon additions. A short course of high-dose dexamethasone in the early stage was useful. Addition of BT or IVIg provided rapid relief. Preexisting HIV disease, kidney disease, and sepsis remain important for in-hospital deaths. Retrospective study design and small number of cases remain major limitations.
format Online
Article
Text
id pubmed-8809144
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-88091442022-02-22 The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study Manvi, Sujaya Mahajan, Vikram K. Mehta, Karaninder S. Chauhan, Pushpinder S. Vashist, Sanket Singh, Ravinder Kumar, Prabal Indian Dermatol Online J Original Article BACKGROUND: Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols. PATIENTS AND METHODS: Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019 were analyzed retrospectively for clinical attributes, putative drugs and their indications, extracutaneous complications, and therapeutic outcome. The diagnosis was clinical based on established criteria. WHO-UMC scale for reporting ADR and ALDEN algorithm score were used for causality assessment. Therapies were customized based on in-house resources and affordability. RESULTS: Cases included were SJS (41.9%), SJS/TEN overlap (33.9%), and TEN (24.2%) aged 4–85 years. Complications included transaminitis (69.4%), lymphadenopathy (15.5%), septicemia (11.3%), and wound infections (4.8%). Aromatic anticonvulsants (37.1%), disease-modifying antirheumatic drugs (25.8%), antiretroviral drugs (12.9%), non-steroidal anti-inflammatory drugs (8.1%), antimicrobials (4.8%), and trihexyphenidyl (3.2%) were major putative drugs. The mean latent period was 16.6 days. The observed 8% mortality was because of primary comorbidities or multiorgan failure. Addition of fresh blood transfusion (BT, n = 11) or IVIg (n = 7) to systemic corticosteroids showed early relief in skin tenderness, improvement in general condition, and re-epithelialization. Only 16% of patients developed sequelae. CONCLUSION: Aromatic anticonvulsants, allopurinol, nevirapine, cotrimoxazole, paracetamol, and diclofenac remain the most implicated drugs. Sulfasalazine, leflunomide, ethambutol, and trihexyphenidyl were uncommon additions. A short course of high-dose dexamethasone in the early stage was useful. Addition of BT or IVIg provided rapid relief. Preexisting HIV disease, kidney disease, and sepsis remain important for in-hospital deaths. Retrospective study design and small number of cases remain major limitations. Wolters Kluwer - Medknow 2022-01-24 /pmc/articles/PMC8809144/ /pubmed/35198464 http://dx.doi.org/10.4103/idoj.idoj_530_21 Text en Copyright: © 2022 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Manvi, Sujaya
Mahajan, Vikram K.
Mehta, Karaninder S.
Chauhan, Pushpinder S.
Vashist, Sanket
Singh, Ravinder
Kumar, Prabal
The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title_full The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title_fullStr The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title_full_unstemmed The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title_short The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study
title_sort clinical characteristics, putative drugs, and optimal management of 62 patients with stevens-johnson syndrome and/or toxic epidermal necrolysis: a retrospective observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809144/
https://www.ncbi.nlm.nih.gov/pubmed/35198464
http://dx.doi.org/10.4103/idoj.idoj_530_21
work_keys_str_mv AT manvisujaya theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT mahajanvikramk theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT mehtakaraninders theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT chauhanpushpinders theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT vashistsanket theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT singhravinder theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT kumarprabal theclinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT manvisujaya clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT mahajanvikramk clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT mehtakaraninders clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT chauhanpushpinders clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT vashistsanket clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT singhravinder clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy
AT kumarprabal clinicalcharacteristicsputativedrugsandoptimalmanagementof62patientswithstevensjohnsonsyndromeandortoxicepidermalnecrolysisaretrospectiveobservationalstudy